Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camoteskimab in Adult Onset Still's Disease
NCT04752371Phase 1Terminated
- Sponsor
- Apollo Therapeutics
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of camoteskimab in adult-onset Still's disease (AOSD) (2 cohorts), sponsored by Apollo Therapeutics. Primary endpoints: Incidence of Adverse Events at 24 weeks, Incidence of Clinically Significant Changes from Baseline in Vital Signs at 24 weeks and 1 more. Started Mar 2021; status: terminated.
02
Drugs
camoteskimab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT04752371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752371.